Fangzhou Inc. has launched Kyinsu®, the world's first once-weekly basal insulin/GLP-1 receptor agonist combination therapy, on its AI-powered Internet hospital platform in China, the first global market for this treatment. This therapy reduces insulin injections from daily to once weekly, aiming to ease the treatment burden for the 148 million adults with diabetes in China. Fangzhou integrates this innovative medicine with its AI-driven chronic disease management system to support long-term patient care and adherence. The launch strengthens Fangzhou's collaboration with Novo Nordisk and aligns with China's Healthy China 2030 initiative to improve diabetes treatment accessibility and outcomes.
In Q2 2026, Eli Lilly reported a strong 48% revenue growth driven by blockbuster obesity drugs Mounjaro and Zepbound, especially with rapid international expansion. Novo Nordisk faced challenges including shrinking U.S. sales, price cuts, layoffs, an...
Eli Lilly has introduced Foundayo, an oral GLP-1 pill for weight loss and type 2 diabetes, in UK pharmacies following recent approval. This tablet offers a convenient alternative to injections and is licensed for adults with certain BMI criteria or w...
Novo Nordisk's stock appears to have formed a long-term bottom as its turnaround gains momentum, with losses in market share to Eli Lilly stabilizing. Trading at just over 15 times forward earnings, the stock is valued at about half of Eli Lilly's mu...
Novo Nordisk maintains a Buy rating driven by strong uptake of its oral obesity drug Wegovy, which has captured 90% of the US oral obesity market with over 5 million prescriptions since launch. The company’s robust GLP-1 franchise and upcoming drug a...
